Research Analysts Set Expectations for SLN FY2025 Earnings

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) – Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Silence Therapeutics in a report issued on Monday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($2.31) per share for the year, up from their prior forecast of ($2.34). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.77) per share. HC Wainwright also issued estimates for Silence Therapeutics’ Q4 2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.25) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at ($1.38) EPS.

Several other research firms have also weighed in on SLN. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Silence Therapeutics in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $32.60.

Silence Therapeutics Stock Performance

SLN opened at $6.73 on Thursday. The company has a market cap of $201.43 million, a PE ratio of -4.99 and a beta of 1.39. The stock has a 50-day moving average of $5.87 and a 200-day moving average of $5.52. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $16.90.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $3.28 million. Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its stake in Silence Therapeutics by 134.1% during the 2nd quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock valued at $48,000 after purchasing an additional 4,773 shares during the last quarter. Beacon Pointe Advisors LLC bought a new position in shares of Silence Therapeutics during the 2nd quarter worth about $67,000. Jump Financial LLC acquired a new position in shares of Silence Therapeutics during the first quarter valued at about $74,000. Evelyn Partners Investment Management Services Ltd lifted its stake in shares of Silence Therapeutics by 481.3% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after buying an additional 11,868 shares during the period. Finally, Massar Capital Management LP acquired a new stake in Silence Therapeutics during the second quarter worth about $115,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.